# Cizzle Bio outlines clinical use and ordering process for CIZ1B lung cancer blood test

- Link: https://www.directorstalkinterviews.com/cizzle-bio-outlines-clinical-use-and-ordering-process-for-ciz1b-lung-cancer-blood-test/4121266343
- Published: 2026-10-14T13:36:00+01:00
- Author: Amilia Stone

Cizzle Bio has published updated guidance for healthcare providers on the clinical
use and ordering of its CIZ1B biomarker blood test, which is designed to provide
additional information when assessing lung cancer risk.

The test measures levels of a specific variant of the CIZ1 protein associated with
lung cancer. Results indicate whether the biomarker is elevated or non-elevated 
and are intended to support clinical assessment alongside a patient’s medical history,
symptoms, risk factors and imaging results.

The test is currently available through licensed healthcare providers in the Dallas-
Fort Worth and San Antonio metropolitan areas. Clinicians must complete an account
registration and onboarding process before accessing the provider portal to place
orders and receive results.

Cizzle Bio identifies several potential applications, including patients with established
lung cancer risk factors, pulmonary nodules, symptoms requiring investigation and
significant occupational or environmental exposures. It may also provide additional
information for patients undergoing screening or follow-up.

The company stresses that CIZ1B is not intended to replace low-dose computed tomography(
LDCT), diagnostic imaging, biopsies or specialist assessment. Results should be 
interpreted by a healthcare professional as part of a comprehensive evaluation, 
with further testing arranged where appropriate.

The guidance sets out the steps for providers to access clinical resources, submit
account details and complete onboarding. Cizzle Bio’s Medical Affairs team is also
available to answer questions about the test’s clinical use.

The publication supports the company’s efforts to establish a provider network for
its lung cancer testing service. Wider adoption will depend on clinical evidence,
healthcare provider engagement and the test’s role within established diagnostic
pathways.

_**Cizzle Biotechnology Holdings plc** (LON:CIZ) is a pioneering cancer diagnostics
company, originally a spin-out from the University of York, and now listed on the
London Stock Exchange._

Share on:
